Skip to main content

Past Events

ASTMH 66th Annual Meeting

November 5-9, 2017
Baltimore Convention Center
Baltimore, MD 21201

IGH at ASTMH and CVD-Mali at ASTMH

Click the links above for a consolidated lists of presentations, posters, and details on the IGH reception.

The Full Public Health Value of Vaccines

Tuesday, November 7, 2017
9:00 - 9:45 AM
Convention Center - Room 343/344 (Level 300)

  • Summary of concepts and moving forward
    Kathleen Neuzil, CVD Director and Deputy Director of the Institute for Global Health

Accelerating Research Toward the Control of Cryptosporidium

Tuesday, November 7, 2017
1:45 - 3:30 PM
Convention Center - Room 321/322/323 (Level 300)

Cryptosporidium has long been recognized as an agent of diarrheal illness in young children and the immunocompromised. The Global Enteric Multicenter Study (GEMS) brought widespread international recognition to Cryptosporidium as a major diarrheal pathogen that stunts linear growth and increases risk for a fatal outcome.

This panel will discuss the epidemiological data substantiating the global burden of diarrheal disease due to Cryptosporidium; describe the current status of in vitro methods in use for identifying potential therapeutics against Cryptosporidium; present the gnotobiotic piglet model for the development of drugs and vaccines against Cryptosporidium; describe our status of development of the human volunteer challenge model for Cryptosporidium; and discuss the regulatory obstacles that have been encountered in the development of the human volunteer challenge model.

  • The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age
  • Khitam Mushen, Department of Epidemiology and Preventive Medicine, Tel Aviv University, Israel
  • In Vitro Screening for Drugs Against Cryptosporidium
  • Christopher Huston, University of Vermont College of Medicine, Burlington, Vermont
  • Understanding Cryptosporidium Through the Use of the Gnotobiotic Piglet Model
  • Saul Tzipori, Department of Infectious Disease and Global Health, Tufts University, North Grafton, MA
  • The development of a human volunteer challenge model for C. hominis
  • Wilbur Chen, Center for Vaccine Development, Baltimore, MD
  • Regulatory and Feasibility Obstacles in Establishing C. hominis Oocysts for Challenge
  • Gerald Quinnan, Emmes Corporation, Rockville, MD

Join us to Take on Typhoid at ASTMH

Controlling Typhoid Disease: New Insights on Vaccines and Vaccination Strategies (#138)

Wednesday, November 8, 2017
10:15 AM - 12 PM
Convention Center - Room 324/325/326 (Level 300)

Typhoid fever disproportionately impacts children and poor populations, a trend that is likely to grow with increasing urbanization. Combined with the growing problem of multi-drug resistance, the prevention and control of Salmonella enterica serovar Typhi (S. Typhi) is a global health priority. At present, vaccines for typhoid fever are underutilized despite the substantial disease burden and a World Health Organization (WHO) recommendation for the use of typhoid vaccines. New vaccines and vaccination strategies are needed to enable programmatic implementation of typhoid control through vaccination. Typhoid conjugate vaccines (TCV)s, which may be given to children as young as six months of age and are expected to have longer duration of immunity than polysaccharide vaccines, should overcome many of the challenges that have impeded uptake of the earlier vaccines. The expected prequalification (PQ) of at least one TCV in the near-term provides a unique opportunity to understand how these vaccines may be used to achieve the greatest impact. Further, already licensed and prequalified vaccines, including an oral vaccine, have been used  to control typhoid. Several new initiatives are underway to ensure that available vaccines are used to achieve the greatest impact and ensure typhoid vaccines finally reach those who need them most. 

Moderators: Kathleen Neuzil, CVD Director and Deputy Director of the Institute for Global Health and Rosanna Lagos, Coordinator, CVD-Chile

  • Evaluating Typhoid Conjugate Vaccines: The Controlled Human Infection Model
  • Andrew Pollard, Director of the Oxford Vaccine Group
  • Typhoid in Nepal: Lessons from a Population-based Study to Inform Vaccine Introduction
  • Buddha Basnyat, Director of the Oxford University Clinical Research Unit - Nepal
  • Evaluation of the First Large Scale Programmatic Implementation of Typhoid Conjugate Vaccines in Navi-Mumbai India
  • Kashmira Date, SEAP’s co-principal investigator, Centers for Disease Control and Prevention
  • Understanding the Role of Chronic Carriers in the Transmission and Control of Typhoid Fever: Lessons from Chile
  • Myron Levine, Associate Dean For Global Health, Vaccinology, and Infectious Diseases

Introduction to the Rotavirus Vaccine Impact on Diarrhea in Africa (VIDA) Study

Thursday, November 9, 2017
8:00 AM - 9:45 AM
Convention Center - Room 321/322/323 (Level 300)

  • Overview of the Objectives and Methods of the VIDA Study
  • Karen Kotloff, VIDA PI
  • Etiology of Moderate-to-severe Diarrhea
  • Richard Omore, VIDA Site PI - Kenya and Rotavirus Program Section Head, Kenya Medical Research Institute (KEMRI)
  • Impact and Effectiveness of Rotavirus Vaccination in the VIDA Study
  • Samba Sow, Director General CVD-Mali
  • Impact of Vaccine Introduction on the Frequency of Adverse Clinical Consequences of Moderate-to-severe Diarrhea
  • Jahangir Hossain, VIDA Site PI - The Gambia, Medical Research Council (MRC) Unit

CVD Seminar Series

Immunogenicity and Protective Efficacy of a Salmonella Enteritidis Core-O Polysaccharide (COPS) and FliC Glycoconjugate in Adult and Infant Mice

Who: Scott M Baliban, PhD
When: Tuesday, September 5, 2017 at 12 pm
Where: HSF II Room S431

Vaccinology (PREV 627)

The CVD's bi-annual vaccinology course (PREV 627) was held from 23 January - 10 May, 2017. The course consists of a series of lectures on a variety of vaccinology topics including:

  • Strategies for vaccine development
  • Pre-clinical evaluation
  • Human clinical trials
  • Current immunization schedules
  • Economics of vaccine development and public health intervention

Special lectures will address highly debated issues of current interest such as vaccine safety, public perception of vaccines, and emerging infectious diseases (e.g., Ebola and Zika). Lectures are presented by experts in the field recruited from industry, academia, and government.

Classes will take place on Mondays and Wednesdays from 9:00 am to 10:00 AM in the HSF II Auditorium, unless otherwise specified.

This is a unique opportunity to acquire up-to-date knowledge in the field of vaccinology. A certificate of training will be provided to those who attend regularly.

2016 IGH Seminar Series

Inaugural IGH Seminar

The Health Impact of Megacities - A Growing Issue

Who: Michele Barry, MD, FACP, FASTMH
Professor of Medicine
Senior Associate Dean of Global Health
Director, Center for Innovation in Global Health
Stanford University School of Medicine
Senior Fellow, Woods Institute for the Environment
Stanford University

When: Monday, February 6, 2017 at 12 pm
Where: HSF II Auditorium, 20 Penn Street

Open to the UMB community

23rd Annual Frontiers in Vaccinology‌

Keynote speaker: Anne Schuchat, MD
Title: From the Holy Grail to Hesitation, and Back?: Journey of Vaccines in America
When: 8-9 Nov 2016
Where: Davidge Hall, 520 W Lombard Street

We Need ETEC and Shigella Vaccines

IGH Seminar Series

Emergency Health System in Unstable Urban Areas: Experience from Karachi, Pakistan

Who: Junaid Razzak, MBBS, FACEP, PhD
Tenured Professor
and Director, Tele-medicine Program
Department of Emergency Medicine
Johns Hopkins University School of Medicine
Professor, Department of International Health
Johns Hopkins Bloomberg School of Public Health
Visiting Scholar
Fogarty International Center, National Institutes of Health

When: Monday, September 18, 2017 at 12 pm
Where: HSF II Auditorium, 20 Penn Street

Open to the UMB community